EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Pridopidine Protects ALS Patient-Derived Neural Progenitor Cells via Sigma-1 Receptor Activation

May Meltzer, Maya Shefler Zamir iD, Noam Tzuri, Andrew M Tan iD, Michal Geva, Michael R Hayden, Rachel G Lichtenstein

International Journal of Molecular Sciences · 14.04.2026 · 27 (8) · 3489

DOI: 10.3390/ijms27083489 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 14.04.2026. Verfasst von May Meltzer und 6 weiteren Autor:innen. Beteiligte Einrichtung: Prilenia Therapeutics B.V., 1411 DC Naarden, The Netherlands. Hauptthemen laut MEDLINE: Receptors, sigma, Amyotrophic Lateral Sclerosis, Neural Stem Cells, Piperidines. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 71 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Prilenia Therapeutics B.V..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The sigma-1 receptor (S1R) is an endoplasmic reticulum (ER)-resident protein enriched at the mitochondria-associated ER membranes (MAMs) that supports ER homeostasis, preserves mitochondrial function, and enhances cell survival under stress. Disruptions of MAM integrity and prolonged ER stress are well-recognized pathological features of amyotrophic lateral sclerosis (ALS), contributing to motor neuron dysfunction and degeneration. In this study, we evaluated the protective effects of pridopidine, a highly selective and potent S1R agonist currently in clinical development for Huntington’s disease (HD) and ALS, using neural progenitor cells (NPCs) derived from induced pluripotent stem cells (iPSCs) from a patient with sporadic ALS. Exposure of ALS NPCs to the ER stressor tunicamycin increased the ER stress markers binding immunoglobulin protein (BiP) and C/EBP homologous protein (CHOP), disrupted mitochondrial membrane potential, upregulated expression of the mitochondrial apoptotic marker, BAX, increased caspase-3 activation, and reduced cell viability. Pridopidine significantly attenuated tunicamycin-induced BiP and CHOP expression in a biphasic, dose-dependent manner (with maximal efficacy at 1 µM), consistent with the typical pharmacology of S1R agonists. Pridopidine restored mitochondrial membrane potential, reduced mitochondrial apoptotic signaling, shown by decreased BAX expression and caspase-3 activation, and improved survival of ALS-NPCs under ER stress. Co-treatment with the selective S1R antagonist, NE-100, attenuated these effects, supporting an S1R-mediated mechanism of action for pridopidine. Together, these results demonstrate that S1R activation by pridopidine mitigates ER-stress-induced mitochondrial dysfunction and cell loss in ALS-NPCs, resulting in enhanced survival of NPCs supporting the therapeutic potential of pridopidine in ALS.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Receptors, sigmaAmyotrophic Lateral SclerosisNeural Stem CellsPiperidinesHumansSigma-1 ReceptorMembrane Potential, MitochondrialEndoplasmic Reticulum StressApoptosisCell SurvivalInduced Pluripotent Stem CellsTunicamycinMitochondriaTranscription Factor CHOPNeuroprotective Agents

Stichwörter der Autor:innen

Sigma-1 receptoramyotrophic lateral sclerosisendoplasmic reticulum stressiPSC-derived neural progenitor cellsmitochondria-associated membranesmitochondrial membrane potentialpridopidine

Substanzen

Receptors, sigmaSigma-1 ReceptorpridopidinePiperidinesTunicamycinTranscription Factor CHOPNeuroprotective Agents

Autor:innen und Institutionen

  • Prilenia Therapeutics B.V., 1411 DC Naarden, The Netherlands.
  • Avram and Stella Goren-Goldstein Department of Biotechnology Engineering, Faculty of Engineering, Ben-Gurion University of the Negev, P.O. Box 653, Beer-Sheva 84105, Israel.
  • Department of Neurology, Yale University School of Medicine, New Haven, CT 06510, USA.
  • Regenerative Medicine and Stem Cell (RMSC) Research Center, Ben-Gurion University of the Negev, P.O. Box 653, Beer-Sheva 84105, Israel.
  • Department of Medical Genetics, Centre for Molecular Medicine and Therapeutics, University of British Columbia, Vancouver, BC V5Z 4H4, Canada.

ORCID-Profile: Maya Shefler Zamir, Andrew M Tan

Förderung

  • Prilenia Therapeutics B.V.

Zitieren

APA

Meltzer, M., Zamir, M. S., Tzuri, N., Tan, A. M., Geva, M., Hayden, M. R., & Lichtenstein, R. G. (2026). Pridopidine Protects ALS Patient-Derived Neural Progenitor Cells via Sigma-1 Receptor Activation. International Journal of Molecular Sciences, 27(8), 3489. https://doi.org/10.3390/ijms27083489

Vancouver

Meltzer M, Zamir MS, Tzuri N, Tan AM, Geva M, Hayden MR, et al. Pridopidine Protects ALS Patient-Derived Neural Progenitor Cells via Sigma-1 Receptor Activation. International Journal of Molecular Sciences. 2026;27(8):3489. doi:10.3390/ijms27083489

BibTeX
@article{Meltzer2026,
  author = {Meltzer, May and Zamir, Maya Shefler and Tzuri, Noam and Tan, Andrew M and Geva, Michal and Hayden, Michael R and Lichtenstein, Rachel G},
  title = {Pridopidine Protects ALS Patient-Derived Neural Progenitor Cells via Sigma-1 Receptor Activation},
  journal = {International Journal of Molecular Sciences},
  year = {2026},
  volume = {27},
  number = {8},
  pages = {3489},
  doi = {10.3390/ijms27083489}
}
Kostenlos starten →